NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Alexander Drilon(Memorial Sloan Kettering Cancer Center)
Cited by 45
Related Papers
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
|Nature Medicine|2020|393
ROS1-dependent cancers — biology, diagnostics and therapeutics
|Nature Reviews Clinical Oncology|2020|288